Fenofibrate protects lipoproteins from lipid peroxidation:: Synergistic interaction with α-tocopherol

被引:18
作者
Chaput, E [1 ]
Maubrou-Sanchez, D [1 ]
Bellamy, FD [1 ]
Edgar, AD [1 ]
机构
[1] Dept Atherosclerosis, Lab Fournier, F-21121 Daix, France
关键词
D O I
10.1007/s11745-999-0390-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One of the earliest steps of atherosclerotic prague formation is an increase of circulating apolipoprotein B-containing lipoproteins which, after infiltrating the subendothelial space, undergo oxidative modification. Fenofibrate is an effective cholesterol- and triglyceride-lowering agent which has been shown to be beneficial in the treatment of atherosclerosis. Vitamin E, or alpha-tocopherol, is a powerful antioxidant which has been shown in a variety of studies to prevent lipoprotein peroxidation. The purpose of the present study was to investigate the effect of fenofibrate treatment, either alone or in combination with alpha-tocopherol, in reducing the susceptibility of lipoproteins to oxidative modification. Rats fed a normal diet were treated for up to 27 d with fenofibrate, either alone or in combination with equimolar doses of alpha-tocopherol. Combined VLDL (very low density lipoproteins) and LDL (low density lipoproteins) isolated after fenofibrate treatment were more resistant to copper-mediated oxidation, as assessed by conjugated diene formation. Lag time was prolonged up to 3.2-fold, while the maximal rate of diene production was significantly decreased by up to 2.2-fold. Treatment of rats with alpha-tocopherol alone at the selected dose had no significant effect on lag time, while the propagation rate was slightly decreased. Coadministration of fenofibrate with alpha-tocopherol prolonged the lag phase to a greater extent than fenofibrate alone, showing a synergistic interaction between the two compounds. Finally, the combination of fenofibrate and alpha-tocopherol was significantly more effective in modifying lipoprotein oxidation parameters than what was observed with alpha-tocopherol and bezafibrate or gemfibrozil. Thus, in addition to its well-established effects on lipoprotein concentrations and atherogenic parameters, fenofibrate reduces the susceptibility of VLDL and LDL to oxidative modification and exerts its action synergistically with alpha-tocopherol.
引用
收藏
页码:497 / 502
页数:6
相关论文
共 46 条
[11]   INDICATIONS FOR THE PRESENCE OF CIRCULATING PEROXIDIZED LOW-DENSITY LIPOPROTEINS IN WHHL RABBITS TREATED WITH ANTIOXIDANTS [J].
DEMACKER, PNM ;
HIJMANS, AGM ;
KLEINVELD, HA ;
STALENHOEF, AFH .
ATHEROSCLEROSIS, 1993, 102 (01) :69-77
[12]  
DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325
[13]  
Esterbauer H, 1997, Adv Pharmacol, V38, P425
[14]   THE ROLE OF LIPID-PEROXIDATION AND ANTIOXIDANTS IN OXIDATIVE MODIFICATION OF LDL [J].
ESTERBAUER, H ;
GEBICKI, J ;
PUHL, H ;
JURGENS, G .
FREE RADICAL BIOLOGY AND MEDICINE, 1992, 13 (04) :341-390
[15]   CONTINUOUS MONITORING OF INVITRO OXIDATION OF HUMAN LOW-DENSITY LIPOPROTEIN [J].
ESTERBAUER, H ;
STRIEGL, G ;
PUHL, H ;
ROTHENEDER, M .
FREE RADICAL RESEARCH COMMUNICATIONS, 1989, 6 (01) :67-75
[16]  
Esterbauer H, 1991, AM J CLIN NUTR S, V53, P314
[17]   Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta [J].
Forman, BM ;
Chen, J ;
Evans, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) :4312-4317
[18]  
FREI B, 1993, J LIPID RES, V34, P2135
[19]   ALPHA-TOCOPHEROL CONSUMPTION DURING LOW-DENSITY-LIPOPROTEIN OXIDATION [J].
JESSUP, W ;
RANKIN, SM ;
DEWHALLEY, CV ;
HOULT, JRS ;
SCOTT, J ;
LEAKE, DS .
BIOCHEMICAL JOURNAL, 1990, 265 (02) :399-405
[20]   EFFECT OF COMBINED SUPPLEMENTATION WITH ALPHA-TOCOPHEROL, ASCORBATE, AND BETA-CAROTENE ON LOW-DENSITY-LIPOPROTEIN OXIDATION [J].
JIALAL, I ;
GRUNDY, SM .
CIRCULATION, 1993, 88 (06) :2780-2786